Business Wire

NIPPON KINZOKU Co-Creating New Value with Rolling Technology Develops Insulated Stainless Steel FI (Fine Insulation) Finish

16.4.2025 02:01:00 CEST | Business Wire | Press Release

Share

NIPPON KINZOKU CO., LTD. (TOKYO: 5491) (Headquarters: Minato-ku, Tokyo) announced that it has developed the "FI (Fine Insulation) finish", a stainless steel with high surface insulation resistance.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250415148656/en/

We have developed our own “FI finish”, a stainless steel surface pre-coated with an inorganic coating (about 1μm in thickness) that offers electrical insulation resistance.

In recent years, miniaturization and low-profile design have become increasingly prominent in electronic devices such as smartphones and game consoles. Until now, measures have been taken to avoid short circuits by installing insulating tape or resin composites at points that come into contact with conductive parts. However, these solutions have led to higher costs and have obstructed miniaturization, and low-profile design.

Against the backdrop of such issues, we have developed our own “FI finish”. Since the “FI finish” does not require post-processing for surface treatment, it is a space-saving product that also contributes to process simplification, improved productivity, and cost reduction for customers. We aim to expand sales in the future, focusing on applications in electronic devices and secondary battery.

“FI finish” is also an “Eco-Product,” certified under our own standards as an environmentally friendly product, because it reduces environmental impact by eliminating the need for insulation treatment at the customer's site. Our goal is to achieve Net Zero CO₂ emissions by 2050, and we will contribute to realizing carbon neutrality through the expanded sales of “Eco-Product”.

Features of FI finish

  1. This is a coating with high surface insulation resistance (50MΩ or more*).
    *Resistance in the thickness direction is measured with a digital multimeter.
  2. The coating has high heat resistance, maintaining stable performance even at high temperatures (up to 850°C).
  3. This hard inorganic coating offers excellent scratch resistance and is suitable for sliding parts.
  4. The thickness of the coating is between 0.5 and 1μm.
  5. Metals other than stainless steel can be considered.

Specifications

1) Steel Grade: SUS304, SUS301, SUS430, etc.
2) Thickness: 0.05 to 0.15mm
3) Width: Max. 500mm
*For specifications other than the above, please consult us.

Overview of Steel Strip Products
Our original designed equipment, built upon our extensive cold-rolling know-how, and our industry-leading proprietary technologies developed through these facilities and our deep expertise, are ready to meet all the diverse needs of our customers.
URL: https://www.nipponkinzoku.co.jp/en/corporate-profile/business/cold-rolled-stainless-steel-strip

View source version on businesswire.com: https://www.businesswire.com/news/home/20250415148656/en/

Contacts

Production Process & Support Dept.
NIPPON KINZOKU CO., LTD.
Email: sisaku-sc@nipponkinzoku.co.jp
https://www.nipponkinzoku.co.jp/en/inquiry -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.nipponkinz
oku.co.jp%2Fen%2Finquiry&esheet=54236840&newsitemid=20250415148656&lan=en-US&anc
hor=https%3A%2F%2Fwww.nipponkinzoku.co.jp%2Fen%2Finquiry&index=2&md5=5552f939f3c
9497d05a82f8f5624071f

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye